FDA approves new type of non-addictive painkiller from Boston drug company
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive risks of opioids.
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
Commuters to get new ferry route from North Station to Seaport
The Massachusetts Convention Center Authority is launching a new ferry route from Lovejoy Wharf to the Raymond L. Flynn ...
WBUR8d
Dig through WBUR readers' 2015 'snowmaggedon' memories and photos
More than 60 WBUR listeners and readers shared their stories — and photos — with us to collectively commemorate, rage and ...
pharmaphorum4d
Digital health round-up: Vertex's machine learning tie-up and more
Vertex has become the latest big pharma company ... Humana will establish the new operation in Boston’s Seaport neighbourhood, according to the website news-medical.net. Dubbed Studio H, Humana ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
STAT1d
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine advisory committee, and more
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way ...
The Motley Fool7d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...
FDA approves drug from Boston-based company to treat pain without opioid effects
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
Wall Street Journal1d
Vertex Pharmaceuticals Inc.
1 Day VRTX -0.71% DJIA 0.38% S&P 500 0.53% Health Care/Life Sciences 0.19% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...